MedAbome is a preclinical-stage biotech company dedicated to developing innovative therapeutic antibody candidates and antibody-related therapies (e.g. ADCs, CAR-T/NK etc.) to meet urgent unmet medical needs. 

Located in the San Francisco Bay Area, MedAbome specializes in the discovery and development of monoclonal antibodies (mAbs) that target unique, disease-specific biomarkers by binding to the conformational or native epitopes. Leveraging advanced hybridoma technology along with our proprietary Live-Cell Immunization (LC-I) and Live-Cell High-Throughput Screening (LC-HTS) platforms, we are building robust pipelines of First-in-Class (FIC) therapeutic candidates. 

Our R&D work spans both oncology and non-oncology indications, including solid tumors, inflammatory and autoimmune diseases — driven by our commitment to deliver impactful therapies to patients in need. 

Copyright © 2025 MedAbome, Inc. - All Rights Reserved.